CN117679350A - Guaiac composition for removing acne marks and smoothing acne pits and application thereof - Google Patents
Guaiac composition for removing acne marks and smoothing acne pits and application thereof Download PDFInfo
- Publication number
- CN117679350A CN117679350A CN202311720109.8A CN202311720109A CN117679350A CN 117679350 A CN117679350 A CN 117679350A CN 202311720109 A CN202311720109 A CN 202311720109A CN 117679350 A CN117679350 A CN 117679350A
- Authority
- CN
- China
- Prior art keywords
- guaiac
- composition
- extract
- parts
- acne
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 118
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 116
- 206010000496 acne Diseases 0.000 title claims abstract description 116
- 241000147041 Guaiacum officinale Species 0.000 title claims abstract description 96
- 229940091561 guaiac Drugs 0.000 title claims abstract description 96
- 238000009499 grossing Methods 0.000 title abstract description 9
- 239000000284 extract Substances 0.000 claims abstract description 78
- 241001474374 Blennius Species 0.000 claims abstract description 47
- 235000004440 Guaiacum sanctum Nutrition 0.000 claims abstract description 39
- 239000002537 cosmetic Substances 0.000 claims abstract description 29
- 229940072113 onion extract Drugs 0.000 claims abstract description 29
- 241000196324 Embryophyta Species 0.000 claims abstract description 18
- 150000002061 ecdysteroids Chemical class 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 241000190019 Guaiacum Species 0.000 claims abstract 6
- 239000000047 product Substances 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 238000000605 extraction Methods 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 13
- 239000001599 crocus sativus l. flower extract Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 12
- 229940076591 saffron extract Drugs 0.000 claims description 12
- CCOQPGVQAWPUPE-UHFFFAOYSA-N 4-tert-butylcyclohexan-1-ol Chemical compound CC(C)(C)C1CCC(O)CC1 CCOQPGVQAWPUPE-UHFFFAOYSA-N 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 235000010469 Glycine max Nutrition 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 244000068988 Glycine max Species 0.000 claims description 9
- 238000002137 ultrasound extraction Methods 0.000 claims description 9
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- 239000003906 humectant Substances 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000002562 thickening agent Substances 0.000 claims description 5
- ZGSCRDSBTNQPMS-UJURSFKZSA-N 3-O-Ethylascorbic acid Chemical compound CCOC1=C(O)C(=O)O[C@@H]1[C@@H](O)CO ZGSCRDSBTNQPMS-UJURSFKZSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical group O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- LQGNCUXDDPRDJH-UHFFFAOYSA-N 3'-GMP Natural products C1C(O)C(O)CC2(C)C(C(O)CC3(C(C(C)(O)C(O)CCC(C)C)CCC33O)C)C3=CC(=O)C21 LQGNCUXDDPRDJH-UHFFFAOYSA-N 0.000 claims description 2
- 229940120155 3-o-ethyl ascorbate Drugs 0.000 claims description 2
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 claims description 2
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 claims description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 2
- RVMAVGROMRTERF-UHFFFAOYSA-N ajugasterone C Natural products CC(C)CCC(O)C(C)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3C(O)CC12C RVMAVGROMRTERF-UHFFFAOYSA-N 0.000 claims description 2
- LQGNCUXDDPRDJH-CNDNGNGWSA-N ajugasterone C Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)C([C@H](O)C[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 LQGNCUXDDPRDJH-CNDNGNGWSA-N 0.000 claims description 2
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 claims description 2
- 229940072107 ascorbate Drugs 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229940067599 ascorbyl glucoside Drugs 0.000 claims description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 2
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 claims description 2
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 claims description 2
- 239000012982 microporous membrane Substances 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 claims description 2
- 102000010637 Aquaporins Human genes 0.000 claims 1
- 108010063290 Aquaporins Proteins 0.000 claims 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims 1
- 235000011613 Pinus brutia Nutrition 0.000 claims 1
- 241000018646 Pinus brutia Species 0.000 claims 1
- 244000013123 dwarf bean Species 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 68
- 239000011148 porous material Substances 0.000 abstract description 26
- 238000005562 fading Methods 0.000 abstract description 9
- 238000007670 refining Methods 0.000 abstract description 7
- 230000019612 pigmentation Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 231100000344 non-irritating Toxicity 0.000 abstract description 3
- 230000036548 skin texture Effects 0.000 abstract description 3
- 238000012797 qualification Methods 0.000 abstract description 2
- 230000000087 stabilizing effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 45
- 210000003491 skin Anatomy 0.000 description 40
- 239000000839 emulsion Substances 0.000 description 34
- 240000006982 Guaiacum sanctum Species 0.000 description 33
- 239000000243 solution Substances 0.000 description 30
- 238000012360 testing method Methods 0.000 description 22
- 241000252212 Danio rerio Species 0.000 description 14
- 230000033001 locomotion Effects 0.000 description 14
- 210000001161 mammalian embryo Anatomy 0.000 description 14
- 206010061218 Inflammation Diseases 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 102000003425 Tyrosinase Human genes 0.000 description 12
- 108060008724 Tyrosinase Proteins 0.000 description 12
- 241000251468 Actinopterygii Species 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- 238000003756 stirring Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000035876 healing Effects 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000012488 sample solution Substances 0.000 description 8
- 241000234282 Allium Species 0.000 description 7
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000009210 therapy by ultrasound Methods 0.000 description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 6
- 230000001815 facial effect Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 231100000241 scar Toxicity 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 5
- 108010013639 Peptidoglycan Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- -1 4-tertiary butyl cyclohexyl Chemical group 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000037307 sensitive skin Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010058679 Skin oedema Diseases 0.000 description 3
- 206010040914 Skin reaction Diseases 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 229960002504 capsaicin Drugs 0.000 description 3
- 235000017663 capsaicin Nutrition 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 230000002910 effect on acne Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000035483 skin reaction Effects 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 238000009777 vacuum freeze-drying Methods 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- 229940120145 3-o-ethylascorbic acid Drugs 0.000 description 2
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 208000020154 Acnes Diseases 0.000 description 2
- 241000223602 Alternaria alternata Species 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 244000089795 Clausena lansium Species 0.000 description 2
- 235000008738 Clausena lansium Nutrition 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 244000124209 Crocus sativus Species 0.000 description 2
- 235000015655 Crocus sativus Nutrition 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- PZHNKNRPGLTZPO-VZRGJMDUSA-N Grifolin Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC1=C(O)C=C(C)C=C1O PZHNKNRPGLTZPO-VZRGJMDUSA-N 0.000 description 2
- PZHNKNRPGLTZPO-UHFFFAOYSA-N Grifolin Natural products CC(C)=CCCC(C)=CCCC(C)=CCC1=C(O)C=C(C)C=C1O PZHNKNRPGLTZPO-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004378 air conditioning Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- SXIFCLOUSXMYIX-UHFFFAOYSA-N cyasterone Natural products CC1OC(=O)C(C)C1CCC(C)(O)C2CCC3(O)C4=CC(=O)C5CC(O)C(O)CC5(C)C4CCC23C SXIFCLOUSXMYIX-UHFFFAOYSA-N 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- 229940091886 4-tert-butylcyclohexanol Drugs 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 239000006000 Garlic extract Substances 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 241000222684 Grifola Species 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- PJAAESPGJOSQGZ-DZGBDDFRSA-N Isovelleral Chemical compound O=CC1=C[C@@H]2CC(C)(C)C[C@@H]2[C@@]2(C)C[C@]21C=O PJAAESPGJOSQGZ-DZGBDDFRSA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 102000003566 TRPV1 Human genes 0.000 description 1
- 229940126422 TRPV1 antagonist Drugs 0.000 description 1
- 240000004429 Tephrosia purpurea Species 0.000 description 1
- 235000017517 Tephrosia purpurea Nutrition 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 101150016206 Trpv1 gene Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 1
- 229940043234 carbomer-940 Drugs 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940059958 centella asiatica extract Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- NEFYSBQJYCICOG-YSEUJXISSA-N cyasterone Chemical compound C[C@H]1OC(=O)[C@@H](C)[C@@H]1C[C@@H](O)[C@](C)(O)[C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)C[C@H](O)[C@H](O)C[C@H]4C(=O)C=C3[C@]2(O)CC1 NEFYSBQJYCICOG-YSEUJXISSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- XJFGDLJQUJQUEI-UHFFFAOYSA-N dodecyl decanoate dodecyl octanoate Chemical compound CCCCCCCCCCCCOC(=O)CCCCCCC.CCCCCCCCCCCCOC(=O)CCCCCCCCC XJFGDLJQUJQUEI-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000020706 garlic extract Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000019866 hydrogenated palm kernel oil Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 125000001474 phenylpropanoid group Chemical group 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 230000000270 postfertilization Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000013215 result calculation Methods 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- JREYOWJEWZVAOR-UHFFFAOYSA-N triazanium;[3-methylbut-3-enoxy(oxido)phosphoryl] phosphate Chemical compound [NH4+].[NH4+].[NH4+].CC(=C)CCOP([O-])(=O)OP([O-])([O-])=O JREYOWJEWZVAOR-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a guaiac composition for fading acne marks and smoothing acne pits and application thereof, and belongs to the technical field of cosmetics; the guaiac composition provided by the invention comprises the following components in parts by mass: 0.2-10 parts of onion extract, 0.1-2 parts of plant ecdysteroid, 0.1-5 parts of guaiacum extract, 0.1-2 parts of VC derivative and 0.1-1 part of light black giant seaweed extract. The guaiac composition provided by the invention has the effects of removing red and black acne marks, smoothing acne pits, improving pigmentation, refining pores and relieving and stabilizing; in addition, the guaiac composition provided by the invention is mild and non-irritating in whole, and can prevent acne recurrence; the guaiac composition can be applied to cosmetics to improve skin qualification and improve skin texture. Meanwhile, the guaiac composition provided by the invention has natural component sources, and the preparation method is simple and suitable for actual production.
Description
Technical Field
The invention belongs to the technical field of cosmetics, and particularly relates to a guaiac composition for fading acne marks and smoothening acne pits and application thereof.
Background
Acne marks, pits, and sensitive skin barrier conditions remain behind after acne, which are of greater concern to the patient than acne. Regardless of the location of the pigmentation, if the underlying factors are not adequately controlled, the pigments darken or spread, which is often long-term and recurrent, potentially causing skin color changes and psychological damage to the patient. Acne patients are prone to pigmentation and tissue damage, and in the early stages the skin is reddish, which is associated with the continued presence of inflammation after resolution of the acne, leading to vasodilation and the presence of red spots in the high tide and resolution phases of inflammation development. The black acne marks are pigmentation caused after inflammation, inflammatory factors stimulate melanocytes and induce melanocytes to synthesize and transport melanin to surrounding keratinocytes, darkening the skin exterior, which may also be permanent. In addition, during inflammation, inflammatory cells secrete degrading enzymes, decompose collagen, elastin, hyaluronic acid and other tissues in dermis, cause dermis injury and thus make skin dent, and form acne pits; at the same time, the residue of the acne marks and the acne pits is also often accompanied by the skin problem of large pores.
In the prior art, a plurality of acne-removing products exist, such as natural components from some sources, such as plant extracts, have the characteristics of anti-inflammatory, bacteriostasis and repairing, but the existing plant extract raw materials or products have weak pertinence to acne marks, especially the repairing effect on acne pits is incomplete and not ideal, and the problem of large pores caused by the existence of the acne marks and the acne pits cannot be solved. Meanwhile, the skin damage problem left after acne is ignored in the prior art, the skin barrier is in a sensitive fragile state after acne for a long time, some products are complex in built-in components and contain acid substances such as azelaic acid, salicylic acid, fruit acid and the like, so that the irritation of the products is increased, the situation of dry desquamation of the skin application area of a subject is avoided, the skin repair and maintenance are not facilitated, and the applicable crowd range of the products is limited. In addition, cosmetic treatments for lightening pigments are generally based on chemical ecdysis, other treatment regimens including laser technology, however, these regimens may all lead to complications, including dermal melanin deposition and inflammation. In addition, the prior art does not pay attention to the effects of eliminating acnes and reducing pores while repairing acne pits.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide the guaiac composition capable of effectively fading red and black acne marks, smoothening acne pits, shrinking pores, avoiding the recurrence of the red and black acne marks, fading the acne marks and smoothening the acne pits gently and not irritating, and the application thereof.
To achieve the above object, in a first aspect of the present invention, there is provided a guaiac composition for reducing acne marks and smoothening out acne pits, comprising the following components in parts by weight:
0.2-10 parts of onion extract, 0.1-2 parts of plant ecdysteroid, 0.1-5 parts of guaiacum extract, 0.1-2 parts of VC derivative and 0.1-1 part of light black giant seaweed extract.
The guaiac composition provided by the invention is prepared by selecting and adding onion extract, plant ecdysteroid, guaiac extract, VC derivative and light black giant seaweed extract in proper mass parts, and 5 components can be mutually cooperated, so that the problems of different types of pigmentation, acne pit residue, enlarged pores and sensitive skin state after acne can be solved. Specifically, the components of the guaiac composition provided by the invention can be matched with each other, so that the guaiac composition can effectively inhibit inflammation, promote the growth and synthesis of intercellular matrixes, accelerate skin metabolism, effectively improve darkness, lighten red and black acne marks, smooth acne pits, reduce pores, relieve redness and stinging of skin caused by acne, strengthen skin tolerance, reduce the sensitive state of the skin, prevent acne and avoid the problem of recrudescence of the red and black acne marks after the acne.
The research of the invention discovers that onion extract contains abundant substances such as quercetin, volatile oil, flavonoid and the like, can promote the generation of MMP-1, down regulate inflammatory factors IL-6, integration factors beta and vascular endothelial growth factors VGEF, inhibit the excessive proliferation of fibroblasts, and has the effects of preventing scar hyperplasia, softening scar, resisting oxidation and relieving skin inflammation. The plant ecdysteroid is a purely natural organic compound extracted from plants, and can increase protein synthesis, strengthen functional systems damaged by pressure, and protect against damage caused by various environments and pressures. The guaiac extract contains rich lignin, quinone, saponin, sesquiterpene and triterpene components, has the effects of resisting inflammation, virus and bacteria, astringing and repairing, can inhibit excessive grease in sebaceous glands, prevent the excessive grease from developing into inflammatory acnes, and has certain healing promotion effect on acne marks and acne pits. The VC derivative has milder and stable effect and good permeability on the basis of the original effect of VC, and can exert good biological activity on skin. The extract of the light black giant seaweed contains active ingredients such as polysaccharides, terpenes, proteins, polyphenols, cyclic polysulfide and the like, and has biological activities such as antioxidation, anti-tumor, blood lipid and blood sugar reduction, immunity improvement and the like. The combination of the components can achieve the excellent effects of fading acne marks, smoothing acne pits and shrinking pores, and has the characteristics of relieving stinging, mildness and no irritation.
As a preferred embodiment of the guaiac composition of the present invention, the guaiac composition comprises the following components in parts by weight: 1-8 parts of onion extract, 0.3-1.5 parts of plant ecdysteroid, 1-3 parts of guaiacum extract, 0.3-1 part of VC derivative and 0.3-0.7 part of light black giant seaweed extract.
As a preferred embodiment of the guaiac composition of the present invention, the guaiac composition comprises the following components in parts by weight: 2-3 parts of onion extract, 0.5-0.8 part of plant ecdysteroid, 1.5-2 parts of guaiacum extract, 0.5-0.6 part of VC derivative and 0.5-0.6 part of light black giant seaweed extract.
According to the research of the invention, the components in the guaiac composition have mass parts which can influence the performance of the product, and when the mass parts of the components are further selected within the range, the obtained product has more excellent effects of fading red and black acne marks and smoothening acne pits, and can also remarkably shrink pores and relieve stinging, thereby being beneficial to acne mark removal, acne pit repair and skin maintenance and relief of sensitive skin people.
As a preferred embodiment of the guaiac composition of the present invention, the guaiac composition further comprises the following components in parts by mass: 0.05-1 part of 4-tertiary butyl cyclohexanol, 0.025-0.5 part of saffron extract and 0.025-0.5 part of green soy bean seed extract.
The research of the invention discovers that 4-tertiary butyl cyclohexyl alcohol is a TRPV1 antagonist, can have good relieving effect on stimulation response induced by TRPV1 activation, the saffron extract is rich in flavonoid compounds, and the grifolin extract is rich in grifolin, and has stronger anti-inflammatory effect; the three components are mixed with onion extract, plant ecdysteroid, guaiacum extract, VC derivative and light black giant seaweed extract for use, so that excellent interaction relationship can be achieved, a better stinging relieving effect of the guaiacum composition is further provided, the repairing capability of sensitive skin of acne patients is improved, and the effects of repairing acne pits, removing acne marks and tightening pores are enhanced.
As a preferred embodiment of the guaiac composition of the present invention, the guaiac composition further comprises the following components in parts by mass: 0.2-0.8 part of 4-tertiary butyl cyclohexanol, 0.1-0.4 part of saffron extract and 0.1-0.4 part of green soybean seed extract.
As a preferred embodiment of the guaiac composition of the present invention, the mass parts ratio of the 4-t-butylcyclohexanol, saffron extract and grifola fron seed extract is 4-t-butylcyclohexanol: saffron extract: green soy bean seed extract = 1: (0.4-0.6): (0.4-0.6).
The present inventors have found that when the parts of 4-t-butylcyclohexanol, saffron extract and green soybean seed extract are further selected within the above-mentioned ranges, and the mass ratio of 4-t-butylcyclohexanol, saffron extract and green soybean seed extract is further selected within the above-mentioned ranges, the resulting guaiacum composition is more excellent in comprehensive effect.
As a preferred embodiment of the guaiac composition of the present invention, the guaiac composition has a mass percentage of onion extract of 26 to 64%.
As a preferred embodiment of the guaiac composition of the present invention, the guaiac composition comprises 6 to 12% by mass of the extract of the light black giant seaweed.
Preferably, the guaiac composition comprises onion extract in an amount of 26 to 40% by mass.
Preferably, the guaiacum composition comprises 6 to 10 mass% of the extract of the light black giant seaweed.
The research of the invention finds that when the mass percentage of onion extract and light black giant seaweed extract in the guaiacum composition is further controlled within the above range, especially the further preferable range, the product has better capability of fading red and black acne marks and better repairing effect on acne pits.
As a preferred embodiment of the guaiac composition of the present invention, the onion extract is prepared by the following method: drying and pulverizing Bulbus Allii Cepae, sieving to obtain Bulbus Allii Cepae coarse powder, adding extraction solvent, performing ultrasonic extraction, vacuum filtering, filtering with microporous membrane, concentrating and drying to obtain Bulbus Allii Cepae extract; the extraction solvent is ethanol water solution with pH value of 5.5-7.5.
According to the invention, the effects of the obtained guaiac composition are different when onion extracts prepared by different extraction methods are added into the guaiac composition, and the comprehensive effect of the obtained guaiac composition is better when the onion extracts are selected to be prepared by the method.
Preferably, onions are screened before drying and crushing, and onions with good quality are selected.
Preferably, the crushing is to crush the dried onion to 100-200 meshes.
Preferably, the solid-to-liquid ratio at the time of ultrasonic extraction is 1: (10-20), the temperature is 40-50 ℃, the time is 1-2h, and the ultrasonic frequency is 40-60kHz.
Preferably, the drying in the concentrated drying of the extracting solution is low-temperature drying in a vacuum drying oven, and the drying temperature is 30-40 ℃.
Preferably, in the ethanol aqueous solution, the volume fraction of ethanol is 60-80%.
The onion extract prepared by the extraction method of the invention has the main active ingredients with the mass percentages as follows: 8-10% of polysaccharides, 80-90% of flavonoids, trace volatile oils and trace phenylpropanoids.
The research of the invention finds that when the parameters in the extraction process are further selected to be the values, the onion extract obtained by extraction is applied to the guaiacum composition, and the obtained guaiacum composition has more excellent comprehensive effect.
As a preferred embodiment of the guaiacum composition of the present invention, the method for preparing the extract of the light black giant seaweed comprises the steps of:
(1) Drying and pulverizing light black giant seaweed, sieving to obtain light black giant seaweed coarse powder, adding an extraction solvent, performing ultrasonic extraction, collecting an extracting solution and filter residues, concentrating and freeze-drying the extracting solution to obtain a freeze-dried product 1;
(2) Mixing the filter residue with distilled water, performing ultrasonic extraction, collecting filtrate, adding 3-5 times of absolute ethyl alcohol, standing at 0-5deg.C overnight, centrifuging to separate supernatant, concentrating, and lyophilizing to obtain lyophilized product 2;
(3) Combining the lyophilized product 1 and the lyophilized product 2 to obtain a light black giant seaweed extract;
in the step (1), the extraction solvent is ethanol water solution with the pH value of 5.5-7.5.
As a preferred embodiment of the guaiacum composition of the present invention, the volume fraction of ethanol in the extraction solvent is 50-70%.
According to the research, when the extraction method is adopted to extract the light black giant seaweed extract, the obtained light black giant seaweed extract can help to realize better effects of removing acne marks, smoothing acne pits and shrinking pores when being applied to a guaiac composition.
Preferably, the crushing is to crush the dried light black giant seaweed to 100-200 meshes.
Preferably, in the step (1), the solid-to-liquid ratio at the time of ultrasonic extraction is 1: (9-12), the temperature is 40-50 ℃, the time is 1-2h, and the ultrasonic frequency is 40-60kHz.
Preferably, in the step (2), the solid-to-liquid ratio at the time of ultrasonic extraction is 1: (35-45), the temperature is 50-70 ℃, the time is 0.5-1h, and the ultrasonic frequency is 40-60kHz.
Preferably, the lyophilization is low temperature drying in a vacuum freeze-drying oven at (-18) -10deg.C.
As a preferred embodiment of the guaiacum composition of the present invention, the plant ecdysteroid comprises at least one of 20-hydroxyecdysteroid, ecdysone, ajugasterone C, terra alba B, pinasterone A, arvenone A, praecoasterone D, cyasterone, and hydroxy cyasterone.
In one embodiment, the plant ecdysteroid is 20-hydroxyecdysteroid.
As a preferred embodiment of the guaiac composition of the present invention, the VC derivative includes at least one of tetraisopalmitate ascorbate, 3-O-ethyl ascorbate, ascorbyl glucoside, ascorbyl palmitate, magnesium ascorbyl phosphate.
In one embodiment, the VC derivative is 3-O-ethyl ascorbic acid.
In a second aspect of the present invention, there is provided a method of preparing the guaiac composition, the method comprising the steps of: the components are uniformly mixed to obtain the guaiac composition.
In a third aspect of the invention, the invention provides the use of the guaiac composition in the preparation of a cosmetic.
The guaiac composition provided by the invention can be used as an effective component to be added into different cosmetics, so that the problems of skin sensitivity caused by acne are solved, such as relieving stinging, removing acne marks, smoothing acne pits and refining pores.
In a fourth aspect of the invention, the invention provides a cosmetic comprising the guaiac composition of the invention.
As a preferred embodiment of the cosmetic according to the invention, the cosmetic comprises the following components in mass percent: 0.1-3% of guaiac composition, 4-40% of cosmetic matrix and the balance of water.
As a preferred embodiment of the cosmetic according to the present invention, the cosmetic base includes at least one of a thickener, a humectant, an emulsifier, a preservative, a perfume, and a pH adjuster.
As a preferred embodiment of the cosmetic according to the invention, the cosmetic comprises the following components in mass percent: 0.1-3% of guaiac composition, 0.05-0.5% of thickener, 3-20% of humectant, 0.5-10% of emulsifier, 0.2-5% of preservative, 0.01-0.2% of essence, 0.05-0.1% of pH regulator and the balance of water.
Illustratively, the thickener comprises at least one of xanthan gum, carbomer 940, AVC, polymeric cellulose; the humectant comprises at least one of glycerin, butanediol and low molecular sodium hyaluronate; the emulsifier comprises at least one of coco-caprylate/caprate, polydimethylsiloxane, hydrogenated palm kernel oil, cetostearyl alcohol, polyglycerol-6 distearate and polymethylsilsesquioxane; the preservative comprises at least one of 1, 3-propanediol, 1, 2-hexanediol and p-hydroxyacetophenone; the pH regulator comprises at least one of arginine and EDTA-2 Na.
As a preferred embodiment of the cosmetic according to the present invention, the cosmetic includes any one of a lotion, an emulsion, a cream, a mask, an essence, and a spray.
In a fifth aspect of the present invention, there is provided a method for preparing a cosmetic, the method comprising the steps of:
(1) Mixing humectant, thickener and part of pH regulator with water, stirring, heating to 80-90deg.C, homogenizing at 1000-1400rpm for 3-5min, and keeping the temperature after homogenizing to obtain prefabricated component A;
(2) Mixing the emulsifying agent, heating to 70-80deg.C, homogenizing at 1000-1400rpm for 3-5min, and maintaining the temperature after homogenizing to obtain prefabricated component B;
(3) Mixing the preservative, heating to 55-65 ℃ and melting to obtain a prefabricated component C;
(4) Heating the prefabricated component A to 75-85 ℃, adding the prefabricated component B at a rotating speed of 200-500rpm, stirring and mixing, cooling to 55-65 ℃, adding the prefabricated component C at a rotating speed of 200-500rpm, stirring and mixing, cooling to below 45 ℃, adding the guaiac composition, continuously stirring for 5-10min, finally adding the rest pH regulator to adjust the pH to 5.0-6.5, stopping stirring, and discharging to obtain the cosmetic.
Compared with the prior art, the invention has the beneficial effects that:
the invention provides a guaiac composition for removing acne marks and smoothing acne pits, wherein 5 components in the guaiac composition can be matched with each other, and the acne mark removing effect in all stages can be achieved within the given range; specifically, acne marks and acne pits can be removed from five dimensions, and the good state of skin can be recovered; the first dimension is that the composition can effectively inhibit skin inflammation and eliminate red acne marks; the second dimension is that tyrosinase can be inhibited, melanin synthesis can be reduced, and black acne marks can be reduced; the third dimension is that the skin matrix regeneration can be promoted, scars can be prevented and reduced, acne pits can be smoothed, and skin textures can be smoothed; the fourth dimension is that the skin barrier can be repaired, the skin sensibility is reduced, and the tough state of the skin is restored; the fifth dimension is that pores of the skin can be reduced, and the skin is fine and smooth. Namely, the guaiac composition plays a good role in preventing and improving the whole process of acne mark formation, has pertinence and comprehensiveness, and can be widely applied to products for removing acne marks, smoothening acne pits, improving pigment deposition after inflammation, refining pores and relieving and stabilizing. Further, after 4-tert-butylcyclohexanol, saffron extract and green soybean seed extract are introduced into the guaiacum composition, a more excellent post-inflammatory relief effect can be obtained; the guaiac composition provided by the invention is mild and non-irritating in whole, has a wide application range, and can prevent acne recurrence; the guaiac composition can also achieve the effect of improving skin qualification and promote skin texture when being applied to the preparation of cosmetics. In addition, the guaiac composition provided by the invention has natural component sources, and the preparation method is simple and is suitable for actual production.
Drawings
FIG. 1 is a graph showing the results of scar repair in mice in effect example 3;
FIG. 2 is a graph showing the result of the movement distance of the zebra fish embryo in effect example 4;
FIG. 3 is a graph showing the results of human arm patch in effect example 5;
FIG. 4 is a graph showing the results of improving red and black blemish marks on the face of a human body in effect example 6;
FIG. 5 is a graph showing the results of repairing the pits on the face of the human body in effect example 7;
fig. 6 is a graph showing the result of refining pores in the human body surface in effect example 7.
Detailed Description
For a better description of the objects, technical solutions and advantages of the present invention, the present invention will be further described with reference to the following specific examples.
The reagents, methods and apparatus employed in the present invention, unless otherwise specified, are all those conventional in the art; and the raw materials used in parallel experiments are the same batch of raw materials without special description.
Onion extract 1: the preparation method comprises the following steps: crushing the dried wampee onion to 100 meshes, and then adding an ethanol aqueous solution with the pH value of 6 and the volume fraction of 70%, wherein the solid-to-liquid ratio is 1:15, then ultrasonic treating at 45+ -3deg.C and 45kHz frequency for 2 hr, filtering after ultrasonic treatment, collecting extractive solution, concentrating, and vacuum drying the concentrate at 35deg.C to obtain Bulbus Allii Cepae extract 1;
Onion extract 2: the preparation method comprises the following steps: crushing dried wampee onion to 100 meshes, and then adding water, wherein the solid-liquid ratio is 1:10, extracting under reflux for 1.5h, filtering after extraction, concentrating the extractive solution, and vacuum drying the concentrate at 35deg.C to obtain onion extract 2;
extract 1 of light black giant seaweed: the preparation method comprises the following steps:
(1) Crushing the dried light black giant seaweed to 100 meshes, and then adding an ethanol aqueous solution with the pH value of 6 and the volume fraction of 55%, wherein the solid-to-liquid ratio is 1:10, then carrying out ultrasonic treatment at 45+/-3 ℃ for 1h at the frequency of 45kHz, filtering after ultrasonic treatment, collecting an extracting solution and filter residues, concentrating the extracting solution, and freeze-drying at-18 ℃ to obtain a freeze-dried product 1;
(2) Mixing the filter residue with distilled water at a solid-to-liquid ratio of 1:40, performing ultrasonic treatment at 60+ -3deg.C and 45kHz frequency for 45min, filtering after ultrasonic treatment, collecting filtrate, adding 4 times volume of absolute ethanol, standing at 4deg.C overnight, centrifuging to separate supernatant, concentrating the supernatant, and lyophilizing at-18deg.C to obtain lyophilized product 2;
(3) Combining the lyophilized product 1 and the lyophilized product 2 to obtain a light black giant seaweed extract 1;
extract 2 of light black giant seaweed: the self-made preparation method is different from the light black giant seaweed extract 1 in the step (1), and the step (1) in the preparation of the light black giant seaweed extract 2 is as follows: crushing the dried light black giant seaweed to 150 meshes, and then adding an ethanol aqueous solution with the pH value of 6 and the volume fraction of 30%, wherein the solid-to-liquid ratio is 1:10, then carrying out ultrasonic treatment at 45+/-3 ℃ for 2 hours at a frequency of 60kHz, filtering after ultrasonic treatment, collecting an extracting solution for concentration, and then collecting a concentrate for vacuum freeze drying at-10 ℃ to obtain the light black giant seaweed extract 2;
Extract 3 of light black giant seaweed: the self-made preparation method is different from the light black giant seaweed extract 1 in the step (1), and the step (1) in the preparation of the light black giant seaweed extract 3 is as follows: crushing the dried light black giant seaweed to 150 meshes, and then adding water, wherein the solid-to-liquid ratio is 1:10, reflux-extracting for 2h, filtering after extraction, collecting the extract, concentrating, and vacuum freeze-drying the concentrate at 10deg.C to obtain light black giant seaweed extract 3;
guaiacum (GUAIACUM OFFICINALE) wood extract, saffron (CROCUS SATIVUS) extract, green soy (TEPHROSIA PURPUREA) seed extract are all commercially available.
Examples 1 to 8 and comparative examples 1 to 5
Examples 1 to 8 and comparative examples 1 to 5 of the present invention provide a guaiac composition whose components (parts by mass) are shown in table 1;
TABLE 1
The guaiac composition provided in example 1 was prepared by: the components are uniformly mixed to obtain the guaiac composition.
The preparation methods of the guaiac compositions provided in examples 2 to 8 and comparative examples 1 to 5 were consistent with example 1.
Example 9
The present example provides a guaiac composition that differs from example 6 only in that onion extract 2 is substituted for onion extract 1.
Example 10
The present example provides a guaiacum composition which differs from example 6 only in that the light black giant seaweed extract 2 is used instead of the light black giant seaweed extract 1.
Example 11
The present example provides a guaiacum composition which differs from example 6 only in that the light black giant seaweed extract 3 is used instead of the light black giant seaweed extract 1.
Comparative example 6
The comparative example of the present invention provides a guaiacum composition which differs from example 6 only in that garlic extract is substituted for onion extract 1.
Comparative example 7
The comparative example of the present invention provides a guaiacum composition which differs from example 6 only in that the guaiacum extract is replaced by centella asiatica extract.
Comparative example 8
The comparative example of the present invention provides a guaiacum composition which differs from example 6 only in that the extract of Alternaria alternata is replaced with the extract of Alternaria alternata.
Comparative example 9
The comparative example of the present invention provides a guaiac composition which differs from example 6 only in that alpha-tocopherol is used instead of 3-O-ethyl ascorbic acid.
Application examples 1 to 12, comparative application examples 1 to 11 and blank application examples
The present invention application examples 1 to 12, comparative application examples 1 to 11 and blank application examples provide emulsions whose components (mass percentages) are shown in table 2; the guaiac compositions in application examples 1 to 11 were the guaiac compositions prepared in examples 1 to 11, respectively, and the guaiac compositions in comparative application examples 1 to 9 were the guaiac compositions prepared in comparative examples 1 to 9, respectively; the guaiac composition used in application example 6 is the guaiac composition prepared in example 6, and so on; the guaiac composition used in application example 12 was the guaiac composition prepared in example 6;
TABLE 2
The preparation method of the emulsion provided in application example 1 comprises the following steps:
(1) Mixing the component A with water, stirring, heating to 80 ℃, homogenizing for 5min at 1200rpm, and preserving heat for later use after homogenizing to obtain a prefabricated component A;
(2) Mixing the component B, heating to 80 ℃, homogenizing for 5min at a rotation speed of 1200rpm, and preserving heat for later use after homogenizing to obtain a prefabricated component B;
(3) Mixing the components C, heating to 60 ℃ and melting to obtain a prefabricated component C;
(4) Heating the prefabricated component A to 80 ℃, adding the prefabricated component B at the rotation speed of 300rpm, stirring and mixing, cooling to 60 ℃, adding the prefabricated component C at the rotation speed of 300rpm, stirring and mixing, cooling to below 45 ℃, adding the guaiac composition, continuously stirring for 5min, finally adding arginine to adjust the pH to 5.0-6.5, stopping stirring, and discharging to obtain the emulsion.
The preparation methods of the emulsions provided in application examples 2 to 12, comparative application examples 1 to 11 and blank application example were kept consistent with application example 1, and the emulsions were not added without the relevant components.
Effect example 1
The effect example of the present invention verifies the inhibitory effect of the guaiac compositions prepared in examples 1 to 11 and comparative examples 1 to 9 on tyrosinase activity, which is a key enzyme in skin melanin biosynthesis, acting on dopa to form dopaquinone, which spontaneously undergoes a series of reactions to finally form melanin; tyrosinase catalyzes the conversion of dopa to dopaquinone in phosphate buffer solution at pH 6.8-7.4, and absorbance at 475nm is measured by spectrophotometer; the raw material with tyrosinase activity inhibition effect can reduce the conversion of dopa into dopaquinone, thereby reducing absorbance value, and can evaluate the inhibition effect of the raw material on tyrosinase activity according to the change of absorbance value.
The testing process specifically comprises the following steps:
diluting 25KU tyrosinase with PBS buffer solution to prepare 200U tyrosinase solution;
10% sample solutions were prepared by diluting examples 1-11 and comparative examples 1-9 with PBS buffer;
preparing a sample tube and a blank control tube according to the following A, B, C, D tube solution, adding 0.5mL of 5% L-dopa solution into each tube after preparing, reacting for 30min at a constant temperature of 37 ℃, measuring absorbance value of the mixed solution at 475nm, and repeating each sample for 3 times; the test results are shown in Table 3:
Wherein, A, B, C, D test tube solution was prepared as follows:
a pipe A: 3mL PBS buffer+0.5 mL tyrosinase;
and B, pipe B: 3.5mL of PBS buffer;
c pipe: 1mL of sample solution+2 mL of LPBS buffer+0.5 mL of tyrosinase;
d pipe: 1mL of sample solution+2.5 mL of PBS buffer;
zeroing: a PBS solution;
calculating tyrosinase inhibition rate: inhibition ratio = 1- (C-D)/(a-B) ×100%;
TABLE 3 Table 3
As can be seen from Table 3, when the technical scheme of the invention is adopted, the inhibition rate of the obtained guaiac composition to tyrosinase is higher and is more than 72.28 percent; the inhibition rate of tyrosinase activity by the obtained guaiacum composition is remarkably reduced when any one of onion extract, plant ecdysteroid, guaiacum extract, VC derivative or light black giant seaweed extract is absent, and the obtained effect is far inferior to that obtained by adopting the technical scheme of the present invention when other similar components are substituted.
Effect example 2
This effect example explores the anti-inflammatory effects of the guaiac compositions prepared in examples 1-11 and comparative examples 1-9, which were shown to activate Toll-like receptors (TLR-2 and TLR-4) on keratinocytes, resulting in activation of MAPK and NF- κB pathways. Keratinocytes then produce inflammatory factors, such as TNF- α, which induce inflammatory production, wherein the primary ligand for TLR-2 is a peptidoglycan of a gram positive bacterium. The effect example evaluates the anti-inflammatory effect of samples by detecting secreted TNF- α in the cell supernatant.
The cell line used was HaCaT cells, passage times: 14, test conditions are: the temperature of the incubator is 37+/-1 ℃, the humidity is 90+/-5% and the carbon dioxide is 5+/-1%. The experiment was set as negative control (NT): culture medium, model set (M): culture +50. Mu.g/mL peptidoglycan, test sample set (TA): sample solution+culture solution+50. Mu.g/mL peptidoglycan, positive control group (PC): 50. Mu.g/mL dexamethasone solution + broth + 50. Mu.g/mL peptidoglycan.
Preparing a test sample solution: taking 0.12g of the samples of each example and comparative example, adding 0.88mL of serum-free MEM to prepare a sample mother liquor with the concentration of 12%, and diluting the mother liquor into a 0.15% sample solution;
dexamethasone solution preparation: 0.025g dexamethasone is weighed, 1mL of methanol is added to prepare 25mg/mL stock solution, and then MEM is used for dilution to obtain working solution;
preparing a culture solution: MEM medium (FBS, gibco, lot: 2500251P) containing 10% fetal bovine serum;
preparing a negative control group culture solution: 5mL of 1% penicillin and 1% streptomycin are added into 500mL of MEM culture medium to prepare a culture medium storage solution, and the culture medium storage solution is mixed for later use;
MMT solution was used for conventional cell culture: MTT was prepared as a 5mg/mL solution of MTT from Sigma using PBS, sterilized by filtration using a 0.22 μm syringe filter, and stored at-20 ℃;
Peptidoglycan (PGN-SA) was purchased from InvivoGen; TNF-alpha kit was purchased from Shenzhen Xinbo.
The results obtained are shown in Table 4;
TABLE 4 Table 4
Group of | TNF-alpha content (pg/mL) | Group of | TNF-alpha content (pg/mL) |
NT | 79.36±4.48* | Comparative example 1 | 96.92±1.88 |
M | 92.33±2.25 | Comparative example 2 | 89.36±4.05 |
PC | 77.27±2.96* | Comparative example 3 | 95.35±6.88 |
Example 1 | 65.63±3.15* | Comparative example 4 | 85.36±5.07 |
Example 2 | 71.36±5.07* | Comparative example 5 | 90.36±4.17 |
Example 3 | 75.29±1.88* | Comparative example 6 | 86.96±2.17 |
Example 4 | 77.35±6.88* | Comparative example 7 | 85.44±5.00 |
Example 5 | 78.02±1.88* | Comparative example 8 | 85.63±3.27 |
Example 6 | 35.27±4.94* | Comparative example 9 | 88.11±1.57 |
Example 7 | 51.28±2.30* | ||
Example 8 | 53.40±3.00* | ||
Example 9 | 69.32±2.75* | ||
Example 10 | 67.02±1.73* | ||
Example 11 | 62.08±5.23* |
Remarks: * The differences were statistically significant (p < 0.05) compared to the model group
As can be seen from table 4, when the technical scheme of the invention is adopted, the obtained guaiac composition can effectively inhibit the inflammatory reaction of keratinocytes, reduce the TNF-alpha content, and has remarkable effect compared with the model group; the inhibition of inflammatory factors by the resulting guaiacum composition is significantly reduced when either one of onion extract, plant ecdysteroid, guaiacum extract, VC derivative or light black giant seaweed extract is absent, and the effect obtained when other similar components are substituted is far from that obtained by the technical scheme of the present invention.
Effect example 3
The effect examples of the invention verify the improvement effect of the emulsion prepared by application examples 1-12, comparative application examples 1-11 and blank application examples on the rat scar model; the method specifically comprises the following steps:
200 SPF-grade SD rats, male, were selected and offered by Guangdong Vetolihua laboratory animal technologies Inc. After purchasing, 8 animals are fed in each cage of the barrier environment animal house, and the animals are used after quarantine is qualified.
After the rats were anesthetized and shaved on the back, after the rats entered deep anesthesia, 2 circular wounds of 7mm were created in the shaved area on the back of the rats using a skin punch, the thickness of the wound being the whole layer of skin. 1 course of treatment per week, each course of treatment was applied for 5 days, and the positive control was human epidermal growth factor gel. Photographs were taken with steel ruler comparisons on the day of molding, day 7 and day 14, respectively. Animals were euthanized on day 14, skin wound was harvested, fixed with fixative, transected and tableted, and HE stained for qualitative analysis of wound inflammation and neonatal tissue status. The healing of days 12, 13 and 14 was measured using Image-Pro Plus 6.0, and the rate of healing was 100%, which was regarded as healing, and the number of mice healed on days 12, 13 and 14 was calculated as the ratio.
Wherein the healing rate (%) = (AO-At)/ao×100%
AO: area of initial wound surface;
At: residual wound area at each time point.
The results obtained are shown in Table 6;
meanwhile, in the pathological scoring of skin injury on the 7 th day, the degree of epithelial necrosis, leukocyte infiltration, neovascularization and skin edema of mice in different groups are experimentally evaluated, and scoring is carried out according to the pathological scoring in the table 5, and the average value is obtained; the results obtained are shown in Table 6;
TABLE 5
TABLE 6
As can be seen from table 6, the emulsion obtained by the technical scheme of the invention has excellent wound healing rate, wherein the 14d healing rate can reach 87.50%; and from the skin injury pathological score of the 7d, the technical scheme of the invention can obviously improve the skin state, lighten the conditions of epithelial necrosis, erosion and leukocyte infiltration, namely obviously improve the inflammatory condition of the skin, promote angiogenesis, effectively improve the skin edema phenomenon and promote skin healing regeneration. When the guaiacum composition obtained in comparative application examples 1 to 5, either lacks any one of onion extract, plant ecdysteroid, guaiacum extract, VC derivative or light black giant seaweed extract, the rate of wound healing by the obtained emulsion is significantly reduced when the guaiacum composition is added to the emulsion; and when the efficacy components used in the added guaiac composition of comparative application examples 6 to 9 are not the components in the present invention but other similar components, the effect obtained by adding them as a whole into the emulsion is far less than that obtained by adopting the technical scheme of the present invention; when comparative application examples 10 to 11 used other effective components having a certain wound repair ability in place of the guaiac composition of the present invention in equal amounts, the effect of the obtained emulsion was also significantly reduced.
In addition, as shown in fig. 1, the result of the scar repairing effect of the emulsion in application example 6 on mice is shown in fig. 1, and it is obvious from fig. 1 that the emulsion provided in application example 6 can obviously promote skin regeneration, improve healing repairing force, improve inflammation, promote angiogenesis and improve skin edema.
Effect example 4
The effect example of the invention verifies the stimulation release rate of the emulsion prepared by application example 1, application examples 6-12, comparative application examples 1-11 and blank application examples on zebra fish embryo; the capsaicin pathway on human skin can be activated by capsaicin, acidity and temperatures above 42 ℃. Zebra fish also have capsaicin pathways and can be activated at high temperatures, peaking at 37 ℃ or above, exhibiting a significant increase in swimming speed. Therefore, the motion distance reduction rate is calculated by applying the motion distance change of the zebra fish and the zebra fish embryo of the model control group activated at high temperature to evaluate the soothing effect of the raw material or the product, and the larger the motion distance reduction rate is, the better the soothing effect is.
The wild type AB strain zebra fish (Danio rerio) test with reliable source (such as China national zebra fish resource center) is applied. The experimental steps are as follows:
healthy 5-day post-fertilization large zebra fish embryos were selected in 96-well plates and exposed to each experimental group, with model controls: randomly selecting 16 fish embryos into 96-well plates, wherein each well contains one fish embryo and 0.2mL of fish embryo culture solution, and the positive control group: 16 fish embryos are randomly selected into 96-well plates, each well containing one fish embryo and 0.2mL of 0.05 g/L4-t-butylcyclohexanol solution, sample group: 16 fish embryos are randomly selected into 96-well plates, each well containing one fish embryo and 0.2ml of 20g/L sample solution (samples were directly lysed with fish embryo culture solution to prepare test sample solutions). After 2h exposure at 28℃the swimming track of each zebra fish in the dark was recorded as the movement distance and statistically analysed using Ethovision XT IR tracking software in a Daniovision zebra fish movement recorder which had been preheated to 38 ℃.
Data and result calculation: measuring and reading the pixel intensity of each hole as the movement distance of each fish embryo;
calculating a motion distance reduction rate: reduction rate= (M-S)/mx100%;
s: average value of the movement distance of the fish embryo of the test object treatment group;
m: average value of embryo movement distance of model group fish.
The results obtained are shown in Table 7;
TABLE 7
/>
Remarks: * The differences were statistically significant (p < 0.05) compared to the model group
As can be seen from Table 7, when the technical scheme of the invention is adopted, the obtained emulsion can remarkably shorten the movement distance of the zebra fish embryo, and the reduction rate is more than 27%. When the guaiacum composition obtained in comparative application examples 1 to 5, whether it lacks any one of onion extract, plant ecdysteroid, guaiacum extract, VC derivative or light black giant seaweed extract, was added to the emulsion, the effect of the obtained emulsion on relieving stinging was significantly reduced; and when the efficacy components used in the added guaiac composition of comparative application examples 6 to 9 are not the components in the present invention but other similar components, the effect obtained by adding them as a whole into the emulsion is far less than that obtained by adopting the technical scheme of the present invention; when comparative application examples 10 to 11 used other similar functional components in place of the guaiac composition of the present invention in equal amounts, the effect of the resulting emulsion was also significantly reduced.
In addition, the graph of the result of the emulsion in application example 6 on the movement distance of the zebra fish embryo at high temperature is shown in fig. 2, and it can be obviously seen from fig. 2 that the emulsion provided in application example 6 can remarkably reduce the movement distance of the zebra fish embryo, so as to achieve the effect of relieving stinging.
Effect example 5
The effect examples of the present invention verify the safety of application example 1, application examples 6 to 12, comparative application examples 1 to 11 and blank application examples on human skin. According to the human skin patch test (cosmetic safety technical Specification) (2015), 33 volunteers 18-60 years old are recruited in the test, and the test environment is the temperature (21+/-1) DEG C and the humidity (50+/-10)%. The volunteer cleans the forearms with clear water, after 5-10 minutes, after the moisture of the forearms volatilizes, the tester applies 0.020-0.025 mL of each group of sample emulsion to each cell of the 10-hole spot tester, selects the inner sides of the two forearms of the volunteer, avoids the skin at the joint movement positions of the front and rear hands, each arm is respectively attached with the spot tester with the sample, and makes corresponding marks, the patch time lasts for 24 hours, the spot tester is removed to wipe residual samples, skin reactions of 0.5 hours, 24 hours and 48 hours are observed, and the results are recorded according to the skin reaction grading standard in cosmetic safety technical Specification (2015). Skin reactions were classified into 4 scoring scales as in table 8, with higher severity of skin irritation reactions as the score was higher.
The test results are shown in Table 9, and it is clear from the test results that the invention provides 0 cases of withdrawal and 0 cases of allergy to rubberized fabric in the technical scheme. When the guaiacum composition obtained in comparative application examples 1 to 5, either lacks onion extract, plant ecdysteroid, guaiacum extract, VC derivative or light black giant seaweed extract, was added to the emulsion, the emulsion obtained had a certain irritation; and when the efficacy ingredient used in the added guaiac composition of comparative application examples 6 to 11 is not the component of the present invention but other similar components, the effect obtained by adding it as a whole to the emulsion is far less than that obtained by adopting the technical scheme of the present invention, wherein application examples 7 to 8 show a 1-stage reaction within 0.5h, application examples 9 to 11 show a 1-stage reaction in an amount of 3 or more within 0.5h, whereas comparative application examples 1 to 11 show a 1-stage reaction in an amount of 5 or more within 0.5h, respectively. In contrast, application examples 6 to 8 and application example 12 were milder and safer, with application example 6 and application example 12 being non-irritating; wherein the picture during the actual test is shown in fig. 3.
TABLE 8
TABLE 9
/>
/>
/>
Effect example 6
The effect examples of the invention verify the application effects of application examples 6-11 and blank application examples for improving acne marks on human bodies, wherein red acne marks and black acne marks are respectively generated in the early stage and the later stage of acne mark formation, the red acne marks are vascular dilatation and inflammatory reaction caused by long acne marks, and if the red acne marks are not maintained or removed in time, the skin is gradually deepened into black acne marks, and the black acne marks are intractable and easy to relapse. The red and black acne marks can be identified according to naked eye identification or non-invasive instrument detection. The present invention was therefore targeted towards the colour exhibited by the acne marks at different times.
The method specifically comprises the following steps:
according to the test of cosmetic safety technical Specification (2015), 80 Asian adult testers 18-60 years old, 10 people in each group, with more obvious acne marks, are selected, under normal conditions, the volunteers continuously use the product for 28 days on the whole face, and the acne mark removing efficacy of different groups of products is evaluated by taking the product containing 3% of nicotinamide (comparative application example 10, which has a great deal of research shows that the nicotinamide lightens pigment, accelerates the exfoliating of horny substances and promotes metabolism to play a role) as a positive control. The method comprises the following specific steps:
the volunteers use the lotion for 1 time in the morning and evening after moisturizing the face, and the lotion is smeared on the acne marks and the acne pits, the massage and the absorption are carried out, and the whole face is used for 1 time in the morning and evening, and the group of 10 people is accessed again in days 3, 7, 14, 21 and 28. The volunteers were not smeared with any product after visiting the test area on the same day and washing the face, and were sitting still for 20min in an air-conditioning room with a temperature of 21+ -1deg.C and a humidity of 50+ -10%. And quantifying and photographing different types of acne marks by adopting an instrument, wherein the values of a are measured by VISIA7, the values of heme content EI and melanin content MI are measured by MX18, and the acne mark area is measured by VISIA7 and IPP. The change in a and EI values may represent the improvement in red blemishes, with smaller data representing more pronounced red blemishes fading; the change in MI value may be indicative of the degree of improvement in black blemish, with smaller values indicating more pronounced black blemish fade. The improvement of the acne marks is represented by the improvement rate of each numerical value in the test, and the calculation mode is as follows:
Mean improvement rate with respect to blank value= (X Before-use mean value -X Mean value after use )/X Before-use mean value ×100%;
The results obtained are shown in Table 10;
table 10
Remarks: * The difference was statistically significant (p < 0.05) compared to the blank value
As can be seen from table 10, the emulsion prepared by the invention can effectively inhibit inflammatory erythema and pigmentation, reduce the area of red and black acne marks, inhibit the conversion of red acne marks into black acne marks and solve the recurrence of acne marks; the effect is obviously better than that of the emulsion added with the nicotinamide, and the acne marks are blackened when the emulsion added with the nicotinamide is not subjected to sun-screening treatment in the use process, the blackened phenomenon of the emulsion does not occur, the emulsion provided by the invention not only stays on the basis of fading the acne marks, but also can obviously reduce the average area of facial color spots, and the effects of homogenizing the facial complexion and improving the facial texture are achieved.
In addition, as shown in fig. 4, the result of the improvement of the emulsion in application example 6 on the red and black acne marks on the face of the human body is shown in fig. 4, and it is obvious from fig. 4 that the emulsion provided in application example 6 can obviously lighten the red and black acne marks and reduce the average area of the facial color spots.
Effect example 7
The effects of the invention prove the application effects of application examples 6-11 and blank application examples on the human body, namely, the effects of smoothing acne pits and refining pores, wherein the acne pits are serious in acne marks, and the skin is usually concave or collapses due to damage to dermis caused by external extrusion, so that the acne marks are easy to be in a permanent state. In addition, loss of collagen and imbalance in oil secretion due to reduced skin elasticity cause problems of enlarged pores after acne, affecting facial gloss and flatness. The experiment uses palmitoyl pentapeptide-4 (comparative application example 11) as a comparison, and the prior study shows that the palmitoyl pentapeptide-4 can obviously promote the generation of dermal matrix protein and help rebuild skin; promoting keratinocyte differentiation and maturation, promoting skin epithelia formation, increasing horny layer thickness and strengthening barrier layer of healthy skin, and has effect in eliminating acne pits.
The method specifically comprises the following steps:
80 subjects with acne pits on the face of 18-60 years old are selected according to the test of cosmetic safety technical Specification (2015), randomly divided into 8 groups, 10 persons in each group use the same product on the random whole face, and palmitoyl pentapeptide-4 (comparative application example 11) is used as a sample of an acne pit control group for 28 days, and the return visit is carried out on days 7, 14 and 28. 10 people, group 1. The volunteers visit the test area on the same day, clean the face without smearing any product, shoot the face image situation (VISIA 7& Primos CR) after sitting still for 20min in an air conditioning room with the temperature of 21+/-1 ℃ and the humidity of 50+/-10%, analyze the red area of the skin, the acne pit volume, the wrinkle depth, the wrinkle volume and the pore number, and the test shows the improvement situation of the acne pits and the pores by the improvement rate of each value, and the calculation mode is as follows:
mean improvement rate with respect to blank value= (X Before-use mean value -X Mean value after use )/X Before-use mean value ×100%;
The results obtained from the test are shown in Table 11;
TABLE 11
Remarks: * The difference was statistically significant (p < 0.05) compared to the blank value
As can be seen from table 11, the technical scheme of the invention can obviously reduce skin redness, slow down subcutaneous inflammation, reduce the volume of acne pits, fill skin, fine pores and smooth skin; when the guaiac composition is not added in the blank application example, the guaiac composition cannot play roles of removing acne pits, reducing skin inflammation and refining pores, and the number of the acne pits and pores instead shows a more serious trend along with the time; meanwhile, compared with comparative application example 11, the technical scheme provided by the invention also shows obvious advantages.
Further, the results of the lotion of application example 6 on repairing and refining the pits and pores of the human face are shown in fig. 5 and 6. The emulsion provided in application example 6 in the experimental result not only can obviously remove acne marks and fill the skin to achieve the effect of preventing acne pits (shown in fig. 5A), but also has remarkable effect of repairing the existing facial acne pits (shown in fig. 5B). Furthermore, it can be seen from fig. 6 that the number of detectable pores is significantly reduced. Therefore, the lotion provided in application example 6 can obviously repair acne pits, reduce skin pits and textures after acne, reduce the number of detectable pores, refine pores and smooth skin.
Finally, it should be noted that the above-mentioned embodiments illustrate rather than limit the scope of the invention, and that those skilled in the art will understand that changes can be made to the technical solutions of the invention or equivalents thereof without departing from the spirit and scope of the technical solutions of the invention.
Claims (17)
1. A guaiac composition for reducing acne marks and soothing acne pits, characterized in that the guaiac composition comprises the following components in parts by weight:
0.2-10 parts of onion extract, 0.1-2 parts of plant ecdysteroid, 0.1-5 parts of guaiacum extract, 0.1-2 parts of VC derivative and 0.1-1 part of light black giant seaweed extract.
2. The guaiac composition of claim 1, wherein said guaiac composition comprises the following components in parts by weight:
1-8 parts of onion extract, 0.3-1.5 parts of plant ecdysteroid, 1-3 parts of guaiacum extract, 0.3-1 part of VC derivative and 0.3-0.7 part of light black giant seaweed extract.
3. The guaiac composition of claim 2, wherein said guaiac composition comprises the following components in parts by weight:
2-3 parts of onion extract, 0.5-0.8 part of plant ecdysteroid, 1.5-2 parts of guaiacum extract, 0.5-0.6 part of VC derivative and 0.5-0.6 part of light black giant seaweed extract.
4. The guaiac composition of claim 1, further comprising the following components in parts by mass: 0.05-1 part of 4-tertiary butyl cyclohexanol, 0.025-0.5 part of saffron extract and 0.025-0.5 part of green soy bean seed extract.
5. The guaiac composition of claim 4, further comprising the following components in parts by mass: 0.2-0.8 part of 4-tertiary butyl cyclohexanol, 0.1-0.4 part of saffron extract and 0.1-0.4 part of green soybean seed extract.
6. The guaiac composition of claim 5, wherein the mass parts ratio of 4-t-butylcyclohexanol, saffron extract and green bean seed extract is 4-t-butylcyclohexanol: saffron extract: green soy bean seed extract = 1: (0.4-0.6): (0.4-0.6).
7. The guaiac composition of claim 1, wherein the mass percent of onion extract in said guaiac composition is 26-64%.
8. The guaiac composition of claim 1, wherein the guaiac composition comprises 6 to 12% by mass of the extract of the light black giant seaweed.
9. The guaiac composition of claim 1 wherein said onion extract is prepared by a process comprising: drying and pulverizing Bulbus Allii Cepae, sieving to obtain Bulbus Allii Cepae coarse powder, adding extraction solvent, performing ultrasonic extraction, vacuum filtering, filtering with microporous membrane, concentrating and drying to obtain Bulbus Allii Cepae extract;
the extraction solvent is ethanol water solution with pH value of 5.5-7.5.
10. The guaiacum composition of claim 1 wherein said extract of light black giant seaweed is prepared by a process comprising:
(1) Drying and pulverizing light black giant seaweed, sieving to obtain light black giant seaweed coarse powder, adding an extraction solvent, performing ultrasonic extraction, collecting an extracting solution and filter residues, concentrating and freeze-drying the extracting solution to obtain a freeze-dried product 1;
(2) Mixing the filter residue with distilled water, performing ultrasonic extraction, collecting filtrate, adding 3-5 times of anhydrous ethanol, standing at 0-5deg.C overnight, centrifuging to separate supernatant, concentrating, and lyophilizing to obtain lyophilized product 2;
(3) Combining the lyophilized product 1 and the lyophilized product 2 to obtain a light black giant seaweed extract;
in the step (1), the extraction solvent is ethanol water solution with the pH value of 5.5-7.5.
11. The guaiacum composition of claim 10, wherein the volume fraction of ethanol in the extraction solvent is 50-70%.
12. The guaiac composition of claim 1 wherein said phytoecdysterol comprises 20-hydroxyecdysterol, ecdysone, ajugasterone C, aquaporin B, pinacoloneA. At least one of Arhat pine sterone A, praecox sterone D, cup amarantrone and hydroxy cup amarantrone 。
13. The guaiac composition of claim 1, wherein said VC derivative comprises at least one of tetraisopalmitate ascorbate, 3-O-ethyl ascorbate, ascorbyl glucoside, ascorbyl palmitate, magnesium ascorbyl phosphate.
14. Use of the guaiac composition according to any one of claims 1 to 13 for the preparation of cosmetics.
15. A cosmetic product, characterized in that it comprises the guaiac composition according to any one of claims 1 to 13.
16. The cosmetic according to claim 15, characterized in that it comprises the following components in percentage by mass: 0.1-3% of guaiac composition, 4-40% of cosmetic matrix and the balance of water.
17. The cosmetic product of claim 15, wherein the cosmetic base comprises at least one of a thickener, a humectant, an emulsifier, a preservative, a fragrance, and a pH adjuster.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311720109.8A CN117679350B (en) | 2023-12-13 | 2023-12-13 | Guaiac composition for removing acne marks and smoothing acne pits and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311720109.8A CN117679350B (en) | 2023-12-13 | 2023-12-13 | Guaiac composition for removing acne marks and smoothing acne pits and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117679350A true CN117679350A (en) | 2024-03-12 |
CN117679350B CN117679350B (en) | 2024-06-07 |
Family
ID=90126131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311720109.8A Active CN117679350B (en) | 2023-12-13 | 2023-12-13 | Guaiac composition for removing acne marks and smoothing acne pits and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117679350B (en) |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007075425A (en) * | 2005-09-15 | 2007-03-29 | Mochida Pharmaceut Co Ltd | Wound covering material including alginic acid |
US20070231417A1 (en) * | 2006-03-09 | 2007-10-04 | Gundula Geske | Use of guaiac wood for treating inflammation of the skin |
US20080153776A1 (en) * | 2006-12-21 | 2008-06-26 | Erning Xia | Method of Treating Inflammation of the Eye |
KR20090060981A (en) * | 2009-05-22 | 2009-06-15 | 김석 | Tape of protecting ultraviolet rays |
JP2015030713A (en) * | 2013-08-06 | 2015-02-16 | 花精舎株式会社 | Skin cosmetic comprising extract of male flower of reynoutria sachalinense |
CN108066187A (en) * | 2018-01-12 | 2018-05-25 | 广州赛莱拉干细胞科技股份有限公司 | A kind of makeup remover and preparation method thereof |
CN109862904A (en) * | 2016-10-21 | 2019-06-07 | 阿尔吉法玛公司 | Bacitracin-alginates oligomer conjugate |
KR102016002B1 (en) * | 2019-05-02 | 2019-08-29 | 주식회사 아이엘바이오 | Cosmetic composition for improving skin-whitening, anti-wrinkle and head skin |
CN110638673A (en) * | 2019-09-25 | 2020-01-03 | 河北瑞龙生物科技有限公司 | Skin care product containing green tea extract and preparation method thereof |
CN112494409A (en) * | 2020-12-31 | 2021-03-16 | 中华全国供销合作总社南京野生植物综合利用研究所 | Onion extract fermentation product and application thereof in daily chemical products |
CN115317417A (en) * | 2022-07-20 | 2022-11-11 | 诺德溯源(广州)生物科技有限公司 | Composition containing guaiacum extract for repairing acne sensitive muscle and skin care product thereof |
CN115581656A (en) * | 2022-09-22 | 2023-01-10 | 羽楠(广州)化妆品有限公司 | Marine organism combination-based emotion awakening iceberg gel with soothing and repairing effects and preparation method thereof |
CN115869233A (en) * | 2023-01-09 | 2023-03-31 | 广州旭妆生物科技有限公司 | Whitening and anti-wrinkle essence and preparation method thereof |
-
2023
- 2023-12-13 CN CN202311720109.8A patent/CN117679350B/en active Active
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007075425A (en) * | 2005-09-15 | 2007-03-29 | Mochida Pharmaceut Co Ltd | Wound covering material including alginic acid |
US20070231417A1 (en) * | 2006-03-09 | 2007-10-04 | Gundula Geske | Use of guaiac wood for treating inflammation of the skin |
US20080153776A1 (en) * | 2006-12-21 | 2008-06-26 | Erning Xia | Method of Treating Inflammation of the Eye |
KR20090060981A (en) * | 2009-05-22 | 2009-06-15 | 김석 | Tape of protecting ultraviolet rays |
JP2015030713A (en) * | 2013-08-06 | 2015-02-16 | 花精舎株式会社 | Skin cosmetic comprising extract of male flower of reynoutria sachalinense |
CN109862904A (en) * | 2016-10-21 | 2019-06-07 | 阿尔吉法玛公司 | Bacitracin-alginates oligomer conjugate |
CN108066187A (en) * | 2018-01-12 | 2018-05-25 | 广州赛莱拉干细胞科技股份有限公司 | A kind of makeup remover and preparation method thereof |
KR102016002B1 (en) * | 2019-05-02 | 2019-08-29 | 주식회사 아이엘바이오 | Cosmetic composition for improving skin-whitening, anti-wrinkle and head skin |
CN110638673A (en) * | 2019-09-25 | 2020-01-03 | 河北瑞龙生物科技有限公司 | Skin care product containing green tea extract and preparation method thereof |
CN112494409A (en) * | 2020-12-31 | 2021-03-16 | 中华全国供销合作总社南京野生植物综合利用研究所 | Onion extract fermentation product and application thereof in daily chemical products |
CN115317417A (en) * | 2022-07-20 | 2022-11-11 | 诺德溯源(广州)生物科技有限公司 | Composition containing guaiacum extract for repairing acne sensitive muscle and skin care product thereof |
CN115581656A (en) * | 2022-09-22 | 2023-01-10 | 羽楠(广州)化妆品有限公司 | Marine organism combination-based emotion awakening iceberg gel with soothing and repairing effects and preparation method thereof |
CN115869233A (en) * | 2023-01-09 | 2023-03-31 | 广州旭妆生物科技有限公司 | Whitening and anti-wrinkle essence and preparation method thereof |
Non-Patent Citations (4)
Title |
---|
ANGELO BERATTO-RAMOS, ET AL: "Selection criteria for high-value biomass: seasonal and morphological variation of polyphenolic content and antioxidant capacity in two brown macroalgae", JOURNAL OF APPLIED PHYCOLOGY, 9 June 2018 (2018-06-09), pages 1 - 12 * |
孙平等: "《图解本草纲目五色蔬菜对症速查全书》", vol. 1, 28 February 2022, 江苏凤凰科学技术出版社, pages: 177 * |
李子安等: "瘢痕的形成机制及天然产物对其治疗的研究进展", 《中国美容医学》, vol. 25, no. 7, 30 July 2016 (2016-07-30), pages 105 - 109 * |
黄丽娃等: "《美容营养学》", vol. 1, 31 January 2018, 华中科技大学出版社, pages: 74 * |
Also Published As
Publication number | Publication date |
---|---|
CN117679350B (en) | 2024-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10695284B2 (en) | Skin external composition for skin moisturization containing red yeast rice extract | |
CN107595737B (en) | Whitening and anti-wrinkle composition containing antrodia camphorata, essence containing composition and preparation method of essence | |
EP2859918B1 (en) | Cosmetic composition containing fermented ginseng berry pleurotus ferulae product | |
CN111388346A (en) | Freeze-dried powder live mask with vegetable protein and polypeptide formula and preparation method thereof | |
CN109330954B (en) | Whitening skin brightening lotion, preparation method thereof and tyrosinase inhibitor | |
EP1135103A1 (en) | Use of plant extracts with an anti-radical-type action | |
KR102253095B1 (en) | Cosmetic composition for improving acned skin, Manufacturing method thereof and functional cosmetics for improving acned skin containing the same | |
JP2011088845A (en) | Involucrin expression inhibitor | |
CN113368018A (en) | Anti-inflammatory acne-removing composition and preparation method thereof | |
CN115212133A (en) | Freeze-dried powder solvent and preparation method and application thereof | |
CN111265441A (en) | Composition capable of enhancing skin night repair and regeneration capacity and application thereof | |
CN108852969B (en) | Anti-wrinkle anti-aging whitening mask and preparation method thereof | |
KR102606356B1 (en) | Cosmetic composition for regenerating skin and improving skin wrinkle | |
KR101727788B1 (en) | Sargassum thunbergii hydrolysates that have high glucuronic acid cotent, preparation method thereof and antiaging cosmetic composition containing the same | |
CN110801412B (en) | Sebum bionic composition, application thereof and cosmetics | |
CN117679350B (en) | Guaiac composition for removing acne marks and smoothing acne pits and application thereof | |
KR101803757B1 (en) | Cosmetic composition containing natural complex fermented extracts | |
CN107802545A (en) | A kind of anti-oxidant and lightening compositions and the skin care item containing said composition | |
KR101552472B1 (en) | Method for producing Crassostrea gigas extract with increased antioxidant and whitening activity | |
CN114767608B (en) | Natural plant maintenance refreshing Yan Fupei skin care product raw material, preparation method and application thereof | |
CN110801516A (en) | Eye nutrient spray liquid and preparation method thereof | |
KR100371504B1 (en) | Cosmetics composition comprising extract powder with vitis vinifera l.fermented solution and having whitening and anti-wrinkle effect | |
JP2011088854A (en) | Involucrin expression inhibitor | |
KR20220001590A (en) | Cosmetic composition comprising Dendropanax morbifera Extract for improving acne skin | |
KR102468264B1 (en) | topical herbal composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |